TY - JOUR
T1 - First-In-Human Study of [64Cu]Cu-DOTATATE PET/CT in Infective Endocarditis
T2 - A Prospective Head-to-Head Comparison With [18F]FDG
AU - Hadji-Turdeghal, Katra
AU - Fosbøl, Marie Øbro
AU - Hasbak, Philip
AU - Löfgren, Johan
AU - Rasmussen, Ida Bull
AU - Bundgaard, Henning
AU - Iversen, Kasper
AU - Bruun, Niels Eske
AU - Møller, Christian H.
AU - Tuxen, Christian
AU - Johannesen, Helle Hjorth
AU - Køber, Lars
AU - Kjær, Andreas
AU - Ripa, Rasmus Sejersten
AU - Fosbøl, Emil Loldrup
N1 - Publisher Copyright:
© 2025 American Heart Association, Inc.
PY - 2025
Y1 - 2025
N2 - BACKGROUND: Infective endocarditis (IE) can be challenging to diagnose. Positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[18F]-fluoro-d-glucose ([18F]FDG) is recommended as a diagnostic tool in the guidelines, but holds limitations. The aim of this study was to compare the tracer uptake between the novel [64Cu]Cu-DOTATATE, which has low cardiac uptake and does not require fasting or dietary restrictions, and [18F]FDG in patients with IE and examine the sensitivity and specificity. METHODS: The CuDOS study (Cu-Dotatate Positron Emissions Tomography in Infective Endocarditis) was a prospective study including 20 patients with IE (10 with prosthetic valve endocarditis and 10 with native valve endocarditis) and 20 controls. All participants underwent [64Cu]Cu-DOTATATE and [18F]FDG PET/CT. Scans were read blinded to clinical data. Tracer uptakes were measured as maximum standardized uptake values in each heart valve. Differences were tested with Wilcoxon rank tests. RESULTS: The median age of the cases and controls was 68 years (interquartile range [IQR], 55.0-75.5) and 61 years (IQR, 57.0-69.5), respectively. [64Cu]Cu-DOTATATE uptake (median maximum standardized uptake value [IQR]) in patients with IE was higher than in controls (2.34 [1.40-3.23] versus 1.44 [1.21-1.60]; P =0.008), although this difference was mainly driven by prosthetic valve endocarditis cases (3.23 [2.02-3.86]; P <0.001) and not between native valve endocarditis cases and controls (1.51 [1.23-2.58]; P=0.428). The sensitivity of [64Cu]Cu-DOTATATE and [18F]FDG PET/CT in 20 cases versus 20 controls were equal, and the specificity was 90% and 75%, respectively. The analysis of prosthetic valve endocarditis versus the 20 controls showed equal sensitivity (80%), and a specificity of 90% and 75%, respectively (P =0.38). In addition, a greater proportion of scans achieved diagnostic certainty with [64Cu]Cu-DOTATATE PET/CT compared with [18F]FDG PET/ CT for native valve endocarditis, prosthetic valve endocarditis, and controls. CONCLUSIONS: [64Cu]Cu-DOTATATE PET/CT showed uptake in the infected valve in patients with IE, and has major advantage as it does not require any preparation compared with [18F]FDG. [64Cu]Cu-DOTATATE had a numerically higher specificity than [18F]FDG, although the difference was not statistically significant. Both tracers were limited in the detection of native valve endocarditis.
AB - BACKGROUND: Infective endocarditis (IE) can be challenging to diagnose. Positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[18F]-fluoro-d-glucose ([18F]FDG) is recommended as a diagnostic tool in the guidelines, but holds limitations. The aim of this study was to compare the tracer uptake between the novel [64Cu]Cu-DOTATATE, which has low cardiac uptake and does not require fasting or dietary restrictions, and [18F]FDG in patients with IE and examine the sensitivity and specificity. METHODS: The CuDOS study (Cu-Dotatate Positron Emissions Tomography in Infective Endocarditis) was a prospective study including 20 patients with IE (10 with prosthetic valve endocarditis and 10 with native valve endocarditis) and 20 controls. All participants underwent [64Cu]Cu-DOTATATE and [18F]FDG PET/CT. Scans were read blinded to clinical data. Tracer uptakes were measured as maximum standardized uptake values in each heart valve. Differences were tested with Wilcoxon rank tests. RESULTS: The median age of the cases and controls was 68 years (interquartile range [IQR], 55.0-75.5) and 61 years (IQR, 57.0-69.5), respectively. [64Cu]Cu-DOTATATE uptake (median maximum standardized uptake value [IQR]) in patients with IE was higher than in controls (2.34 [1.40-3.23] versus 1.44 [1.21-1.60]; P =0.008), although this difference was mainly driven by prosthetic valve endocarditis cases (3.23 [2.02-3.86]; P <0.001) and not between native valve endocarditis cases and controls (1.51 [1.23-2.58]; P=0.428). The sensitivity of [64Cu]Cu-DOTATATE and [18F]FDG PET/CT in 20 cases versus 20 controls were equal, and the specificity was 90% and 75%, respectively. The analysis of prosthetic valve endocarditis versus the 20 controls showed equal sensitivity (80%), and a specificity of 90% and 75%, respectively (P =0.38). In addition, a greater proportion of scans achieved diagnostic certainty with [64Cu]Cu-DOTATATE PET/CT compared with [18F]FDG PET/ CT for native valve endocarditis, prosthetic valve endocarditis, and controls. CONCLUSIONS: [64Cu]Cu-DOTATATE PET/CT showed uptake in the infected valve in patients with IE, and has major advantage as it does not require any preparation compared with [18F]FDG. [64Cu]Cu-DOTATATE had a numerically higher specificity than [18F]FDG, although the difference was not statistically significant. Both tracers were limited in the detection of native valve endocarditis.
KW - copper DOTATATE CU-64
KW - echocardiography
KW - endocarditis
KW - heart valve
KW - positron emission tomography/computed tomography
U2 - 10.1161/CIRCIMAGING.124.017156
DO - 10.1161/CIRCIMAGING.124.017156
M3 - Journal article
C2 - 39902600
AN - SCOPUS:85217507676
SN - 1941-9651
VL - 18
JO - Circulation: Cardiovascular Imaging
JF - Circulation: Cardiovascular Imaging
IS - 2
M1 - e017156
ER -